Researchers at Cleveland Clinic and its partner Anixa Biosciences Inc. are studying a vaccine with the goal of preventing triple-negative breast cancer before it occurs. The researchers are studying the immune response of patients with early-stage triple-negative breast cancer who have been administered the vaccine.